Protagenic Therapeutics, Inc. (PTIX) Income Statement
PTIX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPTIX revenue and net income
PTIX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PTIX quarterly EPS vs estimates
PTIX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $37,715 | $50,286 | $28,218 | $30 | — | $286 | $339 | $347 | $148 | $534 |
| Gross profit | −$37,715 | −$50,286 | −$28,218 | −$30 | — | −$286 | −$339 | −$347 | −$148 | −$534 |
| Research & development | $1.7M | $3.8M | $3.3M | $1.6M | $1.1M | $699,797 | $807,947 | $881,186 | $717,452 | $417,866 |
| Sales, general & admin | $1.7M | $1.8M | $1.2M | $2.0M | $3.0M | $1.9M | $1.3M | $1.4M | $1.6M | $1.4M |
| Total operating expenses | $5.8M | $5.7M | $4.5M | $3.6M | $4.1M | $2.6M | $2.1M | $2.3M | $2.4M | $1.8M |
| Operating income | −$5.8M | −$5.7M | −$4.5M | −$3.6M | −$4.1M | −$2.6M | −$2.1M | −$2.3M | −$2.4M | −$2.2M |
| Interest income | — | $43,465 | $303,246 | $185,790 | $33,207 | $502 | $2,813 | $2,790 | $13,890 | $907 |
| Interest expense | $296,895 | $0 | $107,682 | $137,456 | $496,912 | $246,178 | $15,886 | $2,790 | $13,890 | $7,162 |
| Income before taxes | −$5.2M | −$5.5M | −$5.0M | −$3.6M | −$4.5M | −$2.5M | −$1.8M | −$2.6M | −$2.3M | −$2.3M |
| Income taxes | — | — | $2 | $46,051 | $463,705 | $246,178 | $15,886 | $486,808 | −$106,000 | $440,239 |
| Net income | −$5.2M | −$5.5M | −$5.0M | −$3.6M | −$4.5M | −$2.5M | −$1.8M | −$2.6M | −$2.3M | −$2.3M |
| EBITDA | −$7.1M | −$5.5M | −$4.5M | −$3.4M | −$4.1M | −$2.6M | −$2.1M | −$2.3M | −$2.4M | −$2.3M |
| EPS (diluted) | −$3.45 | −$1.89 | −$1.13 | −$3.02 | −$5.81 | −$0.30 | −$0.16 | −$0.25 | −$0.21 | −$0.26 |
| Jun '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $25,143 | $0 | $3,200 | $0 | $0 | $0 |
| Cost of revenue | $8,312 | — | $12,572 | $12,571 | $12,572 | $25,143 | $12,571 | $12,571 | $12,572 | — | $1,419 | $91 |
| Gross profit | −$8,312 | — | −$12,572 | −$12,571 | −$12,572 | −$50,286 | −$12,571 | −$12,571 | −$12,572 | — | −$1,419 | −$91 |
| Research & development | $109,925 | $153,786 | $273,229 | $394,112 | $880,372 | $903,362 | $364,184 | $1.2M | $1.5M | $1.0M | $1.1M | $836,379 |
| Sales, general & admin | $97,980 | $154,817 | $159,915 | $814,262 | $567,736 | $752,388 | $300,454 | $465,869 | $290,185 | $200,799 | $307,682 | $307,363 |
| Total operating expenses | $952,935 | $925,103 | $1.1M | $2.3M | $1.4M | $1.6M | $652,066 | $1.7M | $1.7M | $1.2M | $1.4M | $1.1M |
| Operating income | −$961,247 | −$925,103 | −$1.1M | −$2.3M | −$1.4M | −$1.6M | −$652,000 | −$1.7M | −$1.7M | −$1.2M | −$1.4M | −$1.1M |
| Interest income | — | $23,831 | $34,337 | — | $8,103 | $9,026 | $11,281 | $9,291 | $13,867 | $53,657 | $69,218 | $84,708 |
| Interest expense | $10,763 | $23,831 | $34,337 | $238,727 | — | $0 | $0 | $0 | $12,852 | $12,852 | $31,957 | $31,610 |
| Income before taxes | −$963,616 | $2.2M | −$869,496 | −$5.1M | −$1.4M | −$1.6M | −$641,000 | −$1.6M | −$1.7M | −$1.7M | −$1.4M | −$1.2M |
| Income taxes | — | — | — | — | — | $2 | $2 | −$1 | −$2 | — | $52,957 | $31,610 |
| Net income | −$963,616 | $2.2M | −$869,496 | −$5.1M | −$1.4M | −$1.6M | −$641,000 | −$1.6M | −$1.7M | −$1.7M | −$1.4M | −$1.2M |
| EBITDA | −$952,935 | −$912,532 | −$856,921 | −$4.8M | −$1.4M | −$1.5M | −$628,000 | −$1.6M | −$1.7M | — | −$1.4M | −$1.2M |
| EPS (diluted) | −$0.53 | $1.14 | −$0.47 | −$1.37 | −$2.75 | −$0.24 | −$0.14 | −$0.36 | −$0.38 | — | −$0.32 | −$0.28 |
| Gross margin | — | — | — | — | — | — | −50.0% | — | −392.9% | — | — | — |
| Operating margin | — | — | — | — | — | — | −2,593.2% | — | −54,312.5% | — | — | — |
| Net margin | — | — | — | — | — | — | −2,549.4% | — | −53,875.0% | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PTIX's financial statements (latest annual report filed March 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PTIX financial results
Protagenic Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $5.2 million. Diluted earnings per share came to −$3.45.
See the PTIX stock overview for the latest quote and news, or the PTIX chart for price history and technical indicators.
PTIX income statement FAQ
Does Protagenic Therapeutics have revenue?
Protagenic Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Protagenic Therapeutics profitable?
No. Protagenic Therapeutics reported a net loss of $5.2 million in fiscal 2025.
How much does Protagenic Therapeutics spend on research and development?
Protagenic Therapeutics spent $1.7 million on research and development in fiscal 2025.
What are Protagenic Therapeutics's earnings per share?
Protagenic Therapeutics earned $-3.45 per diluted share in fiscal 2025, compared with $-1.89 a year earlier.
When does Protagenic Therapeutics's fiscal year end?
Protagenic Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 9, 2026.